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ABSTRACT 
Backround: Mortality studies in patients with hemochromatosis gave conflicting results especially with respect 
to extrahepatic causes of death. Our objective was to assess mortality and causes of death in a cohort of HFE 
C282Y homozygotes diagnosed since the availability of HFE testing.  
Methods: We studied 1085 C282Y homozygotes consecutively diagnosed from 1996 to 2009 and treated 
according to current recommendations. Mortality and causes of death were obtained from death certificates and 
compared to those of the general population. Standardized mortality ratios (SMR) were used to assess specific 
causes of death and Cox's model to identify prognostic factors for death. 
Results: Patients were followed for 8.3±3.9 years. Overall SMR was the same as in the general population (0.94 
- CI:0.71-1.22). Patients with serum ferritin 2000 µg/L had increased liver-related deaths (SMR: 23.9-CI:13.9-
38.2), especially due to hepatic cancer (SMR: 49.1-CI:24.5-87.9). Patients with serum ferritin between normal 
and 1000µg/L had lower mortality than the general population (SMR: 0.27-CI:0.1-0.5) due to decreased 
mortality related to cardiovascular events and extrahepatic cancers in the absence of increased liver-related 
mortality. Age, diabetes, alcohol consumption, and hepatic fibrosis were independent prognostic factors of death.  
Conclusion: In treated HFE hemochromatosis, only patients with serum ferritin higher than 2000µg/L have 
increased mortality, mainly related to liver diseases. Those with mild iron burden have decreased overall 
mortality in relation to reduced cardiovascular and extrahepatic cancer-related mortality.  These results support a 
beneficial effect of early and sustained management of patients with iron excess, even when mild. 
Word count: 244 
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Major advances have been made to our understanding of iron metabolism and the diagnosis and management of 
genetic hemochromatosis since early studies by Niederau et al.[1] Progress in molecular genetics has 
increased the precision and reliability of diagnosis of most genetic defects responsible for iron overload. HFE 
hemochromatosis has been shown to account for up to 95% of hemochromatosis in adults,[2-4]  to be mainly 
related to the C282Y mutation,[5] to be characterized by low clinical penetrance (1% in women, 28% in men),[6, 
7] and to be diagnosed nowadays at an earlier stage, thanks to widespread family screening and serum-ferritin 
analysis. [8] 
However, despite a significant number of epidemiological studies, the real impact of HFE hemochromatosis on 
mortality is still unclear, especially with respect to the respective roles of hepatic and extra hepatic diseases in 
mortality of patients and to the level of iron burden associated with decreased survival. These conflicting results 
may in part be explained by the various designs of studies. In the pivotal study by Niederau et al.[9] overall 
mortality was increased, and the main causes of death were cirrhosis, liver cancer, and, cardiomyopathy. In the 
absence of HFE testing, it is likely that other causes of iron overload, especially non-HFE hemochromatosis and 
iron-overload secondary to end-stage cirrhosis, were also included. In addition, due to the phenotypic definition 
of HFE hemochromatosis, the most severe clinical cases were selected, resulting in overrepresentation of 
cirrhosis (56%) and diabetes (47%). This likely induced an overestimation of mortality rates. Milman et al. have 
draw the same conclusions [10], but their study had the same limitations. More recently, Elmberg et al. [11] 
reported on 3832 patients with putative hemochromatosis who had been diagnosed using heterogeneous methods 
between 1964 and 2005. They found an overall increased mortality, which, surprisingly, further increased 
through time. Fracanzani et al. reported on 452 patients diagnosed prospectively between 1977 and 2007, [8] of 
whom 269 only were demonstrated to be C282Y HFE homozygotes. They found lower overall survival rates 
without any difference between HFE and non-HFE hemochromatosis. However, HFE testing was not available 
and other causes of iron overload or cofactors may have influenced both diagnoses and mortality rates. On the 
other hand, large scale genotyping studies conducted in general populations included all C282Y homozygotes, 
but had low power due to the small number of cases with variable clinical expression, resulting in a risk to 
underestimate disease consequences [7, 12, 13].  In addition, information regarding iron burden and its treatment 
were either lacking or insufficient. [6, 7] Recently serum ferritin levels higher than 1000µg/l were reported to be 
associated with increased risk of death in a cohort of 422 North American C282Y homozygotes. [14] 
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This led us to reassess the mortality and causes of death in a large, well-defined, and prospective cohort of 
C282Y HFE homozygous patients and to compare their results with those of the French general population. 
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All C282Y HFE homozygous patients referred as probands to our tertiary center or who were diagnosed through 
family-screening procedures run by our center since 1996 were prospectively included in the LOGIFER cohort. 
Patients diagnosed before 1996 were not included because of the likelihood of selection bias caused by 
retrospective HFE testing. Data from patients' files were recorded by data-managers with double data entry. 
Clinical research assistant (MP) provided quality control, and bio-statistician (JM) performed coherence control 
and statistical analyses. 
According to French law, the corresponding database was declared to the national committee of “Informatics and 
Freedom” (CNIL). The study protocol was approved by the local ethics committee (11.27-22/09/2011)  
			
At diagnosis 
The following data were collected at diagnosis: date, age, gender, proband or relative status, alcohol 
consumption, tobacco smoking, body-mass index, blood pressure, clinical presentation and symptoms (asthenia, 
diabetes, cardiomyopathy, liver disease, hypogonadism, arthropathy), iron status (serum ferritin, transferrin and 
iron, transferrin saturation), and routine biochemical features. 
 
Liver fibrosis was determined by a liver biopsy using the METAVIR scoring system (F0: no fibrosis to F4: 
cirrhosis).[15] In the absence of histological data, patients with serum ferritin <1000 µg/L were considered to be 
free of F3–4 fibrosis (= severe fibrosis) according to Guyader’s algorithm, [16] those with hepatocellular 
carcinoma as having severe fibrosis, and others as having missing data. 
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During follow-up 
Venesection therapy was advised when serum ferritin was higher than 300µg/L in men and 200µg/L in women, 
or, when both transferrin saturation was higher than 50% and functional symptoms attributable to 
hemochromatosis, i.e. chronic fatigue and distal arthralgias, were present. After serum ferritin <50 µg/ level was 
achieved, patients were advised to continue venesection therapy to maintain serum ferritin <50 µg/L in the long 
term. Follow-up data were recorded when available: date, number and volume of phlebotomies, and usual 
clinical and biochemical indicators of tolerance and efficacy of venesection therapy. 
The amount of iron removed refers to the number of grams of iron removed until low body-iron stores were 
achieved. It was calculated assuming that 1 L of blood contained 0.5 g of iron. For patients with normal iron 
parameters at diagnosis, yearly biological surveillance was proposed and treatment was initiated if the above 
criteria were fulfilled. 
End point 
End point was fixed as December 31, 2010, because of delay needed to obtain data on the causes of death. Vital 
status and causes of death were obtained from death certificates which are collected for the entire French 
population and supplied by INSEE (National Institute of Statistics and Economical Studies) and INSERM 
(National Institute of Health and Medical Research). Data on rates and causes of death for the French general 
population were obtained from the national statistical tables published by these two institutes and based on death 
certificates. These tables were stratified by date, geographic area, gender, and into 10-year age groups. Causes of 
death were displayed according to the CIM-10 classification and grouped by broad category which were all 
studied separately (all causes, non-liver related disease (i.e. all medical causes except liver related disease), liver 
related disease (i.e. liver failure and liver cancer), liver cancer, extra hepatic cancer, cardiovascular disease, other 
disease (i.e. neither cardiovascular nor liver related disease, including external causes (i.e. traumatism, suicide, 
etc.)) 
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Statistical analyses were performed using SAS V9.3 (SAS Institute, USA).


The numbers of deaths observed in the cohort, and in subgroups of patients, were compared to the numbers of 
deaths expected from the general population (Standardized Mortality Ratios [SMRs]). All calculations were 
stratified by strata according to 5 French administrative geographical areas, sex, 10 year-age groups, and one-
year calendar periods. Therefore, for each stratum, the number of expected deaths was calculated by multiplying 
the patient-years at-risk by the corresponding national mortality rate. Then SMR determined for a given 
subgroup was calculated as the ratio of observed deaths divided by the sum of the expected number of deaths in 
the corresponding strata. SMRs were calculated for general causes of death, including deaths from external 
causes. The 95% confidence interval (CI) was determined on the basis of a 5% bilateral test using the Byar 
approximation. 

Prognostic factors of death were first determined by univariate analyses using Student's t-test or Wilcoxon's test 
for continuous variables, and the chi-squared test or Fisher’s exact test for categorical variables. Then 
multivariate survival analyses were performed using Cox's regression model to estimate the hazards ratio (HR) 
with a 95% CI. 
Variables with p <0.2 in the univariate analyses were introduced into the multivariate models. We used multiple 
imputation inference for variables with less than 30% missing data. Missing data were filled in 30 times to 
generate 30 complete data sets with MI procedure from SAS 9.3.  Then, the 30 complete data sets were analyzed 
by using Cox regression procedures, and the results from these sets were combined for the inference study, by 
using MIANALYZE procedure from SAS 9.3. 
A p value of <0.05 was considered as significant.  
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1085 HFE C282Y homozygous patients were consecutively diagnosed between 1996 and 2009. Their main 
characteristics are presented in Table 1. Initial referral causes were iron-related symptoms in 306 patients, 
abnormal iron tests at routine check-up in 401 patients, family screening in 336 patients and unknown in 42 
patients. Based on serum ferritin levels at diagnosis, 212 had normal value, 531 patients were considered to have 
slight iron burden (serum ferritin levels from normal to less than 1000µg/L), 135 mild iron burden (serum ferritin 
levels between 1000 and 2000µg/L), 123 severe iron burden (serum ferritin levels > 2000µg/L), 84 having no 
serum ferritin determination available at diagnosis. At diagnosis, 789 patients had serum ferritin levels greater 
than the normal range and were thus advised to undergo venesection therapy. Despite all subjects were not 
treated in our unit, we can ensure that phlebotomies were really started and iron removal achieved in 698 of 
them. Therefore, our study must be analysed on “intent to treat” rather than “per protocol” basis.  
%$	$!				#	
Overall mortality and causes of death are reported in Table 2. Incidence rates of liver disease and liver cancer 
related deaths were 2.92 and 2.16 per 1000 person years respectively. Incidence rate of extra hepatic cancer and 
cardiovascular related deaths were 0.97 and 0.54 per 1000 person years respectively. Despite overall mortality 
was the same that the general population, hepatic causes of death were increased whilst extrahepatic causes of 
death were reduced. Hepatic and nonhepatic-related deaths occurred at the age of 63.8(±10.1) and 67(±14) years, 
respectively (p=0.33), without difference in the mean age at diagnosis (59±9.8 and 61.8±13.7 years, respectively 
(p=0.4)) or in the duration of median follow-up (4.7±3 and 5.2±3.2 years, respectively (p=0.55)). Mean serum 
ferritin levels of patients who died from hepatic causes was 3816±1932µg/L, and 2417±3723µg/L (p=0.11) in 
patients who died from non-liver related causes. 
SMRs did not vary according to male or female gender, proband/relative status, year of birth and year of 
diagnosis. 
SMRs were similar to that of the general population for age at diagnosis lower than 45 years, between 45 and 55, 
and higher than 56. All had similar mortality to that of the general population but had increased risk of death 
from liver cancer compared to the general population. 
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As the expressivity of HFE hemochromatosis is highly variable, the specific causes of death were studied 
according to initial iron burden and clinical expression. SMRs for relevant variables are presented in Table 3. 
 
Serum ferritin levels at diagnosis.  
Patients with serum ferritin levels between normal and 1000µg/L had lower overall mortality, which 
corresponded to reduced cardiovascular and extra hepatic cancer-related mortality whereas liver-related 
mortality remained similar to that of the general population. Patients with serum ferritin levels from 1000 µg/L 
to 2000 µg/L had similar SMRs to those of the general population. Patients with serum ferritin levels greater 
than 2000µg/L had higher mortality, mostly related to liver cancer, and without decreased cardiovascular and 
extra hepatic-related mortality.  
Patients with normal serum ferritin at diagnosis had similar SMR to that of the general population except for 
liver cancer (SMR: 48.78 (5.48-176.12)). This result was due to 2 patients with normal serum ferritin at 
diagnosis who died from liver cancer, while 0.04 liver cancer-related death was expected. The first patient was a 
female with serum ferritin of 186 µg/L at diagnosis. She had overt metabolic syndrome and died 11 years later, 
at the age of 74 years, from hepatocellular carcinoma. It is likely that she had no cirrhosis at the time of the 
diagnosis of HH and that she developed cirrhosis related to nonalcoholic steato-hepatitis during follow-up. The 
second patient had unclear history of severe mixed, alcoholic and hemochromatotic cirrhosis revealed by 
digestive bleeding with early death after admission.  His initial low serum ferritin level may have been related to 
bleeding or to unknown previous venesection therapy, hence leading to somehow inadequate categorization of 
the patient as “normal serum ferritin”. With the exception of these two patients, for which the link between 
cirrhosis and HFE hemochromatosis was highly questionable, the eighteen remaining patients who died from 
hepatocellular carcinoma had serum ferritin higher than 2000 µg/L at diagnosis. 
Transferrin saturation at diagnosis.  
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Patients with serum transferrin saturation lower than 75% at diagnosis had reduced mortality compared to the 
general population (SMR:0.56 (CI:0.30-0.96)), whereas patients with transferrin saturation greater than 75% had 
similar mortality (SMR:1.03 (CI:0.70-1.46)) . 
Amount of iron removed.  
Patients with mild amount of iron removed (2-10g, n=397) had lower overall mortality (SMR:0.23 (0.08-0.5) 
than the general population, whilst the mortality of patients with high amount of iron removed (>10g) did not 
differ from that of the general population (SMR:1.01 (0.37-2.2)). 
!"
Cirrhosis: Liver biopsy was performed in 254 patients. Patients with cirrhosis (n=51) had higher mortality than 
that of the general population (SMR:4.43 (2.53-7.19)) mainly due to increased liver disease- and liver cancer-
related mortality (SMR:7.39 (1.99-18.93) and SMR:86.02 (37.04-169.51) respectively). The overall mortality of 
patients with F0 to F2 fibrosis was lower than that of the general population (SMR:0.45 (0.16-0.97)). 
Diabetes: Patient with diabetes had increased mortality (SMR:4.07 (2.45-6.35)) mainly related to increased liver 
disease and liver cancer-related mortality (SMR:41.67 (20.77-74.56) and SMR:92.11 (36.9-189.78) 
respectively). By contrast, those without diabetes had lower mortality than the general population (SMR:0.52 
(0.32-0.79)), although they had increased liver cancer-related mortality (SMR:4.98 (1.34-12.75) and lower extra 
hepatic cancer-related mortality (SMR: 0.21 (0.04-0.61)). 
Arthropathy: Patients with arthropathy and patient without arthropathy at diagnosis had similar mortality to that 
of the general population (SMR:0.81 (0.47-1.3) and SMR:0.86 (0.53-1.31) respectively). 
Cardiomyopathy: Patients with cardiomyopathy at diagnosis (N=34) – whether it was related or not to 
hemochromatosis - had significantly increased mortality (SMR:3.37 (1.54-6.41)). 
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Cardiovascular causes of death: Five patients died from cardiovascular disease (SMR:0.38 (CI:0.12-0.89)) 
(Table 2). Serum ferritin levels <1000µg/L at diagnosis, and amount of iron removed between 2 and 10g were 
associated with lower cardiovascular mortality. Other variables were not found to influence cardiovascular 
mortality. 
Hepatic causes of death (including liver cancer): Twenty seven patients died from liver-related deaths 
(SMR:6.85 (CI:4.51-9.97)) (Table 2). They were mainly males (21/27) with severe iron burden at diagnosis 
(mean serum ferritin: 3816±1932µg/L). Ten had excessive alcohol consumption, 19 had severe fibrosis and 11 
had diabetes. Among these 27 patients, 20 patients died from hepatic cancer compared to 1.25 expected in the 
general population (SMR:15.96 (CI:9.75-24.65)). Severe fibrosis at initial liver biopsy was associated with 
higher mortality as were type I and type II diabetes. 
Extrahepatic cancers: Nine patients died from extrahepatic cancers compared to 21.81 expected in the general 
population (Table 2). Patients with a mild amount (2-10g) of iron removed and/or serum ferritin levels 
<1000µg/L had lower mortality related to extrahepatic cancers than the general population (SMR:0.21 (CI:0.02-
0.78) and 0.19 (CI:0.02-0.69) respectively).  
($		#	$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Cox's proportional hazards model was performed to assess the prognostic factors associated to death. Variables 
significant (p <0.2) at univariate analyses were introduced into multivariate models. Age at diagnosis 56 (HR: 
7.72 [4.35-13.71]), diabetes (HR: 4.69 [2.51-8.77]), alcohol consumption (HR: 3.20 [1.68-6.09]), and liver 
fibrosis  F3 (HR: 6.80 [3.62-12.76]) were independently associated with the risk of death. Figure 1 shows 
Kaplan Meier cumulative survival curves according to factors associated with mortality. 
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Our study indicates that HFE C282Y homozygous patients diagnosed since 1996 - when HFE testing became 
available - and who were treated according to current international recommendations, did not have increased 
overall mortality rate compared to general population. Moreover, it demonstrates that, by contrast to patients 
with serum ferritin higher than 2000µg/L who have increased mortality, mainly related to liver diseases, patients 
with serum ferritin between normal and 1000µg/L have decreased overall mortality in relation to reduced 
cardiovascular and extrahepatic cancer - related mortality in the absence of increased liver-related mortality. This 
was not observed in patients with normal serum ferritin at diagnosis.  
The present study has several strengths. First, it relies upon a well-documented prospective cohort of 1085 
patients, diagnosed consecutively by genotyping and presenting a wide spectrum of biochemical and clinical 
phenotypic expression of the disease, including 789 (73%) patients with increased serum ferritin levels at 
diagnosis, of whom 258 (24%) had serum ferritin levels >1000µg/L. This allowed subgroups analyses, especially 
according to initial iron burden and clinical presentation. Second, thanks to the French social insurance system, 
the record of death causes was exhaustive in both patients and the general population used as reference. Third, 
we used the SMR method to compare the mortality of patients to that of general population, allowing sex- and 
age-specific adjustment across time period and geographic area, and then, avoiding competing biases between 
causes of death. Otherwise, two main limitations have to be underlined. First, the mean duration of follow-up 
was rather short (8.3±3.9 years) with respect to a disease with a long-standing course, and thus, the number of 
deaths remained low (59/1085).  Second, detailed history of maintenance therapy was fragmented even if data 
regarding the initiation of treatment was available for a large number of patients. 
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Overall mortality and prognostic factors 
Overall life expectancy was normal in the present cohort. This could not be related to earlier diagnosis, since age 
at diagnosis was similar to those observed by Niederau et al.[9] and Fracanzani et al.[8] Explanations may be a 
higher proportion of females who are known to have less severe disease,[17] and/or a trend towards less severe 
disease through time [8] possibly due to lower prevalence of associated co-morbidities. The higher proportion of 
of females found in the present study is in line with the autosomal transmission of HH and better reports on the 
reality of the disease. It is likely the consequence of widespread genetic testing in both index and family cases 
and better awareness of the disease, leading to diagnose less severe forms. This increasing proportion of females 
over time was already described in the study by Fracanzani et al.[8] 
However, 789 (73%) of our patients had increased serum ferritin levels at diagnosis, including 258(24%) with 
serum ferritin >1000µg/L, which makes our cohort representative of the current HFE hemochromatosis 
population with a wide range in clinical expression. Finally, the overall mortality in our cohort could also have 
been influenced by the beneficial effect of early and sustained venesection therapy. 
Cox regression model showed that age at diagnosis 56 years, diabetes, alcohol consumption, and liver fibrosis 
F3 were independently associated with the risk of death. One may be surprised by the absence of serum ferritin 
in the model, but serum ferritin being used in the definition of fibrosis stage, it was more statistically sound not 
to consider it for the analysis. 
 
Causes of death and iron burden 
As expected, mortality was mostly (47%) related to liver disease, mainly hepatic cancer (74%). Of note, liver-
related deaths mainly occurred in patients with marked iron burden, severe fibrosis and associated co-morbidities 
such as diabetes. This emphasizes the critical importance of fibrosis staging at the time of diagnosis and, in those 
patients with severe fibrosis, of biannual ultra sound examination, even after achievement of iron removal.  
SMRs related to extrahepatic causes of death were significantly decreased in the whole cohort. Interestingly, this 
was due to decreased cardiovascular and extrahepatic cancer–related mortality only in patients with serum 
ferritin levels comprised between the upper limit of normal and 1000µg/L (Table 3). As these patients did not 
have higher mortality due to liver disease, this could not be due to a competing effect between causes of death. 
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Moreover, this decreased mortality was not observed in patients with normal serum ferritin levels at diagnosis 
which were not advised to be venesected. Similar results were obtained when studying patients with amount of 
iron removed between 2 and 10g. 
 
By contrast, patients with iron removed > 10g or serum ferritin higher than 1000µg/L had similar cardiovascular 
and extrahepatic cancer-related mortality as the general population. Such a difference was not due to earlier 
liver-related mortality as hepatic and nonhepatic-related deaths occurred at the same age and duration of follow-
up, and because this was even observed in patients with serum ferritin between 1000 and 2000µg/L who did not 
have increased risks for liver cancer-related mortality. 
Previous results on cardiovascular mortality in hemochromatosis have been conflicting, [9, 10] and the relevance 
of C282Y HFE mutation as a risk factor for cardiovascular events is still debated. [18, 19] Serum ferritin is 
likely a marker of cardiovascular complications possibly through its link with insulin resistance. [20] However, 
Valenti et al. did not find any association between increased serum ferritin levels and the development of carotid 
plaque in patients with HFE mutations unlike in those free of HFE mutations. [21] This suggests that, in 
hemochromatosis, a balance between the potential benefits of HFE mutations and the deleterious effect of iron 
overload could exist. [22] Our results support a protective effect of HFE hemochromatosis on the development 
of cardiovascular disorders. This could be due to the iron-poor phenotype of macrophages in HFE 
hemochromatosis, [23] protecting these cells from the deleterious effect of iron. [24] However, this beneficial 
effect was observed in our patients with serum ferritin levels comprised between the normal range and 
1000µg/L, but not in those with normal serum ferritin values at diagnosis. This would support a beneficial effect 
of sustained iron depletion rather than of the sole HFE status. 
Contrary to previous follow-up studies of hemochromatosis patients, [25, 26] we found a lower extra-hepatic 
cancers mortality. This was not related to early death secondary to liver disease. According to initial iron burden, 
only the subgroup of patients with serum ferritin levels comprised between normal and 1000µg/L had decreased 
extra-hepatic cancer-related mortality, which again would suggest a beneficial role of chronic iron depletion. 
Many epidemiological and experimental studies support a role of iron as a carcinogen. Conversely, iron 
depletion has been shown to be associated with a dramatic decrease in the incidence of extra-hepatic cancers in 
patients with peripheral arterial disease.[27] However, such a beneficial effect in hemochromatosis patients 
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could be also related to medical follow-up or to lifestyle modifications due to the awareness of a genetic 
condition or even to a biological advantage of the HFE C282Y mutation.  
 
 
The present results must be interpreted on in “intent to treat” basis. They suggest that early and sustained iron 
removal is beneficial to hemochromatosis patients, especially in cases of slight or mild iron overload, and that 
any reduction in the venesection schedule should be introduced cautiously. However, more precise data from all 
patients regarding long-term stringency of maintenance therapy, morbidities that occurred during follow-up, and 
evolution of exposure to co-morbidity factors after the initial removal of excess iron would have been necessary 
to state about the real effect of iron depletion on survival. 
In conclusion, we have shown, in a large population of treated patients, that overall mortality is not increased in 
HFE hemochromatosis. Actually, this reflects opposite situations: patients with serum ferritin higher than 
2000µg/L have increased liver-related mortality, and those with serum ferritin between normal and 1000µg/L, 
when treated, have decreased cardiovascular and extra-hepatic related mortality despite normal liver-related 
mortality. Our results support a beneficial effect of early management and sustained follow-up of patients with 
iron excess, even when slight, whatever this protective effect is really related to iron removal or not. 
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Table 1: Main clinical and biochemical characteristics of patients. 

Gender (males / females - % (n)) 48% / 52% (516/569) 
Probands/relatives % (n) 69% / 31% (749/336) 
Age at diagnosis (years) (mean ± SD) 45.2 (±14.2) 
Follow up duration (years) (mean ±SD) 8.3 (±3.9) 
10-year survival (%) 94.7 
Serum ferritin (µg/L) 
Mean ±SD 
Normal / <1000 / 1000–2000 / >2000 (n) 
Missing data (n) 
 
981 (±1419) 
212/ 531/ 135/ 123 
8% (84) 
Amount of iron removed (g)  
(mean ±SD) 
Missing data (% [n]) 
 
5.0 (±5.1) 
36% (387) 
Liver fibrosis (Metavir score - % (n)) 
F3-F4 (%) 
<F3 
Missing data 
 
8% (82) 
76% (831) 
16 % (172) 
Diabetes % (n) 
Type I & Type II diabetes 
No diabetes 
Missing data 
 
4 % (46) 
70 % (762) 
26 % (277) 
Alcohol consumption % (n) 
>30 g/day (>20g / day in women) 
<30g/day (<20g/day in women) 
Missing data 
 
8% (88) 
64% (693) 
28% (304) 


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